Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Circulating Cell-free Genome Atlas Study (CCGA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02889978
Recruitment Status : Active, not recruiting
First Posted : September 7, 2016
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
GRAIL, Inc.

Tracking Information
First Submitted Date August 18, 2016
First Posted Date September 7, 2016
Last Update Posted Date February 15, 2019
Study Start Date August 2016
Actual Primary Completion Date February 11, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 26, 2018)
  • To collect and study clinically-annotated biospecimens, specifically peripheral blood and contemporary tumor tissue when available, to characterize cfNA profiles from deep sequencing and to estimate the population heterogeneity in two arms of the study. [ Time Frame: 30 months ]
  • To develop and evaluate models for discriminating cancer versus non-cancer and tissue of origin. [ Time Frame: 30 months ]
  • To evaluate concordance of variants identified in sequencing of tumor tissue and cfNA sequencing results in plasma from the same subject. [ Time Frame: 30 months ]
Original Primary Outcome Measures
 (submitted: August 31, 2016)
Evidence of histologically confirmed cancer in subjects with circulating tumor DNA (ctDNA) detected by deep sequencing. [ Time Frame: 18 months ]
Clinically annotated plasma samples from cancer and non-cancer subjects will undergo deep sequencing to characterize cfNA profiles and to estimate the population heterogeneity in the two arms of the study.
Change History Complete list of historical versions of study NCT02889978 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: September 26, 2018)
  • To explore the relationship between genomic results and clinical outcomes based on collection of longitudinal information (at least annually for up to 5 years) from medical records for all consenting participants. [ Time Frame: Year 1, 2, 3, 4, 5 ]
  • To enable assessment of the performance of an analytically validated clinical laboratory version of the NGS assay (under development) to detect circulating tumor DNA (ctDNA) in plasma. [ Time Frame: Year 1, 2, 3, 4, 5 ]
Original Secondary Outcome Measures
 (submitted: August 31, 2016)
  • Number of genomic variants detected in plasma cfNA in cancer subjects who also have available tumor tissue. [ Time Frame: 18 months ]
    Concordance of variants identified in sequencing plasma cfNA and tumor tissue from the same subject will be evaluated.
  • Survival or clinical cancer status (none, mild, moderate, or severe) of all subjects with results from deep sequencing plasma cfNA. [ Time Frame: Year 1, 2, 3, 4, 5 ]
    Explore the relationship between genomic results and clinical outcomes based on collection of longitudinal information (at least annually for up to 5 years) from medical records.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Circulating Cell-free Genome Atlas Study
Official Title The Circulating Cell-free Genome Atlas Study
Brief Summary GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer participants and to develop models for distinguishing cancer from non-cancer.
Detailed Description This is a prospective, multi-center, observational study with collection of de-identified biospecimens and clinical data from at least 15,000 participants from clinical networks in the United States and Canada. The study will enroll approximately 10,500 cancer participants (CANCER arm) and approximately 4,500 representative participants without a clinical diagnosis of cancer (NON-CANCER arm). Clinical information, demographics, and medical data relevant to cancer status are collected from all participants and their medical record at baseline (time of biospecimen collection), and subsequently from the medical record at intermittent future time points, at least annually for up to 5 years.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Plasma, white blood cells, formalin fixed, paraffin embedded (FFPE) tumor tissue
Sampling Method Non-Probability Sample
Study Population Eligible study participants will be recruited from participating medical centers in a ratio of 3 non-cancer participants for every 7 cancer participants within each individual research center. Non-cancer subject recruitment will be monitored to achieve demographic characteristics (eg, age, gender, ethnicity, smoking status) reflective of those of the cancer participants.
Condition
  • Neoplasms
  • Cancer
Intervention Not Provided
Study Groups/Cohorts
  • Cancer arm
    Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
  • Non-cancer arm
    Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Active, not recruiting
Estimated Enrollment
 (submitted: December 18, 2017)
15000
Original Estimated Enrollment
 (submitted: August 31, 2016)
10000
Estimated Study Completion Date March 2024
Actual Primary Completion Date February 11, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria for Non-Cancer Arm Participants:

  • Age 20 years or older
  • Able to provide a written informed consent

Exclusion Criteria for Non-Cancer Arm Participants:

  • Known current or prior diagnosis of cancer except non-melanoma skin cancer
  • Oral or IV corticosteroid use in past 14 days prior to blood draw
  • Pregnancy (by self-report)
  • Current febrile illness
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
  • Poor health status or unfit to tolerate blood draw

Inclusion Criteria for Cancer Arm Participants:

  • Age 20 years or older
  • Able to provide a written informed consent

Have either of the following:

A. Confirmed cancer diagnosis (any stage I-IV, as well as carcinoma in situ (CIS) within 90 days prior to study blood draw, based upon assessment of a pathological specimen

OR

B. A high suspicion for a cancer diagnosis by clinical and/or radiological assessment, with planned biopsy or surgical resection to establish a definitive diagnosis within 6 weeks (42 days) after study blood draw

Exclusion Criteria for Cancer Arm Participants:

  • Known prior diagnosis of cancer except non-melanoma skin cancer
  • Currently receiving, or ever received, any of the following therapies to treat their current cancer: surgical management of the cancer beyond that required to establish the cancer diagnosis; local, regional or systemic chemotherapy including chemoembolization; targeted therapy, immunotherapy including cancer vaccines; hormone therapy; or radiation therapy
  • Pregnancy (by self-report)
  • Current febrile illness
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
  • Poor health status or unfit to tolerate blood draw
Sex/Gender
Sexes Eligible for Study: All
Ages 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02889978
Other Study ID Numbers GRAIL-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party GRAIL, Inc.
Study Sponsor GRAIL, Inc.
Collaborators Not Provided
Investigators
Study Director: Kate Kurtzman, MD GRAIL, Inc.
PRS Account GRAIL, Inc.
Verification Date February 2019